Wall Street Zen Upgrades Tempest Therapeutics (NASDAQ:TPST) to “Sell”

Tempest Therapeutics (NASDAQ:TPST) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Monday, July 13th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tempest Therapeutics presently has an average rating of “Reduce”.

Tempest Therapeutics Price Performance

NASDAQ:TPST opened at $0.76 on Friday. Tempest Therapeutics has a twelve month low of $0.74 and a twelve month high of $12.23. The firm has a market capitalization of $12.84 million, a price-to-earnings ratio of -0.18 and a beta of -1.73. The stock’s 50 day moving average price is $0.95 and its two-hundred day moving average price is $1.29.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.04). As a group, analysts anticipate that Tempest Therapeutics will post -0.83 earnings per share for the current year.

Hedge Funds Weigh In On Tempest Therapeutics

A hedge fund recently bought a new position in Tempest Therapeutics stock. Squarepoint Ops LLC bought a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned about 0.19% of Tempest Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue.

Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR?).